Both Acasti Pharma Inc. (NASDAQ:ACST) and Acer Therapeutics Inc. (NASDAQ:ACER) are each other’s competitor in the Biotechnology industry. Thus the contrast of their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Acasti Pharma Inc. | 2 | 0.00 | 71.50M | -1.22 | 0.00 |
| Acer Therapeutics Inc. | 3 | 0.00 | 3.46M | -2.71 | 0.00 |
Demonstrates Acasti Pharma Inc. and Acer Therapeutics Inc. earnings per share (EPS), gross revenue and valuation.
Profitability
Table 2 provides the return on equity, return on assets and net margins of the two firms.
| Net Margins | Return on Equity | Return on Assets | |
| Acasti Pharma Inc. | 3,626,312,319.32% | 0% | 0% |
| Acer Therapeutics Inc. | 122,482,211.76% | -67.4% | -61.7% |
Analyst Ratings
The following table shown below contains the ratings and recommendations for Acasti Pharma Inc. and Acer Therapeutics Inc.
| Sell Ratings | Hold Ratings | Buy Ratings | Rating Score | |
| Acasti Pharma Inc. | 0 | 0 | 1 | 3.00 |
| Acer Therapeutics Inc. | 0 | 0 | 1 | 3.00 |
Acasti Pharma Inc.’s upside potential currently stands at 316.67% and an $7.75 average target price. Acer Therapeutics Inc. on the other hand boasts of a $48 average target price and a 1,543.84% potential upside. Based on the results shown earlier, Acer Therapeutics Inc. is looking more favorable than Acasti Pharma Inc., analysts opinion.
Institutional & Insider Ownership
Acasti Pharma Inc. and Acer Therapeutics Inc. has shares owned by institutional investors as follows: 4.02% and 61.1%. Insiders owned roughly 13.28% of Acasti Pharma Inc.’s shares. Insiders Comparatively, owned 0.3% of Acer Therapeutics Inc. shares.
Performance
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
| Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
| Acasti Pharma Inc. | 2.99% | 107.76% | 181.87% | 129.52% | 338.18% | 189.7% |
| Acer Therapeutics Inc. | 2.4% | -23.92% | -84.35% | -87.67% | -84.67% | -85.14% |
For the past year Acasti Pharma Inc. has 189.7% stronger performance while Acer Therapeutics Inc. has -85.14% weaker performance.
Summary
On 7 of the 10 factors Acasti Pharma Inc. beats Acer Therapeutics Inc.
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia. Acasti Pharma Inc. was incorporated in 2002 and is based in Laval, Canada.
Acer Therapeutics Inc. develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease (MSUD). It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD). The company was founded in 2013 and is based in Cambridge, Massachusetts.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
